View Older Stories View More Recent Stories

Apr 25, 2024 06:30AM Merck Announces First-Quarter 2024 Financial Results
Apr 17, 2024 08:00AM MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour
Apr 16, 2024 08:00AM MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing
Apr 4, 2024 06:45AM Merck (MRK) Initiates Phase 3 Clinical Trial of MK-1084
Apr 4, 2024 06:45AM Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metasta
Apr 3, 2024 08:04AM Daiichi Sankyo and Merck (MRK) Announce REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Apr 3, 2024 08:00AM REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Apr 1, 2024 06:45AM Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Mar 28, 2024 06:46AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy for NSCLC
Mar 28, 2024 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Ca
Mar 26, 2024 06:21PM FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Mar 21, 2024 06:45AM Merck (MRK) Provides Update on Phase 3 KEYLYNK-006 Trial of KEYTRUDA Plus Maintenance LYNPARZA
Mar 21, 2024 06:45AM Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Can
Mar 20, 2024 11:03AM MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea
Mar 19, 2024 09:02AM Merck (MRK) Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Mar 19, 2024 09:00AM Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
Mar 15, 2024 06:45AM Merck (MRK) Reports KEYTRUDA Plus Chemoradiotherapy Significantly Improved OS Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Mar 15, 2024 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Can
Mar 13, 2024 03:00AM Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9
Mar 11, 2024 08:15AM Merck (MRK) Completes Acquisition of Harpoon Therapeutics
Mar 11, 2024 08:15AM Merck Completes Acquisition of Harpoon Therapeutics, Inc.
Mar 6, 2024 10:25AM Gilead Sciences (GILD) and Merck (MRK) Report Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Mar 6, 2024 10:25AM Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
Mar 5, 2024 08:30AM Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Mar 5, 2024 06:45AM Merck to Participate in the Barclays 26th Annual Global Healthcare Conference
Mar 4, 2024 06:45AM Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
Feb 27, 2024 07:00AM Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 27, 2024 06:45AM Merck to Participate in the TD Cowen 44th Annual Health Care Conference
Feb 23, 2024 06:23AM Merck (MRK) Reports Positive EU CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectabl
Feb 23, 2024 06:20AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment
Feb 15, 2024 08:45AM Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
Feb 5, 2024 06:33AM Merck Animal Health (MRK) Acquires Elanco’s (ELAN) Aqua Business for $1.3B Cash
Feb 5, 2024 06:33AM Merck Animal Health to Acquire Elanco’s Aqua Business
Feb 1, 2024 06:30AM Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results
Jan 29, 2024 05:54AM Merck's (MRK) KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC)
Jan 27, 2024 10:00AM Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephr
Jan 26, 2024 10:00AM Merck (MRK) Reports KEYTRUDA Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothel
Jan 26, 2024 10:00AM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced
Jan 23, 2024 02:44PM Merck Announces Second-Quarter 2024 Dividend
Jan 19, 2024 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1
Jan 15, 2024 08:15AM Merck Animal Health's Fourth Veterinary Wellbeing Study Indicates Progress in Addressing Mental Health Challenges Among Veterinary Teams
Jan 12, 2024 05:30PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer
Jan 8, 2024 07:34AM Merck (MRK) to Acquire Harpoon Therapeutics (HARP) for $23/sh Cash or $680M
Jan 8, 2024 07:30AM Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
Jan 5, 2024 06:46AM Merck (MRK) Announces Phase 3 Trial Initiations for Four Investigational Candidates
Jan 5, 2024 06:45AM Merck Announces Phase 3 Trial Initiations for Four Investigational Candidates From its Promising Hematology and Oncology Pipeline
Jan 3, 2024 06:45AM Merck to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Dec 22, 2023 08:01AM Merck (MRK) Reports Patritumab Deruxtecan Granted Priority Review in the U.S.
Dec 22, 2023 08:00AM Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Dec 20, 2023 04:30PM Merck (MRK) Receives CRL for Gefapixant
View More Recent Stories View Older Stories